WallStSmart

Clearpoint Neuro Inc (CLPT)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 157352% more annual revenue ($66.57B vs $42.28M). MRK leads profitability with a 4.8% profit margin vs -81.8%. CLPT appears more attractively valued with a PEG of 0.61. MRK earns a higher WallStSmart Score of 36/100 (F).

CLPT

Avoid

33

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -2.62

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLPTUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$15.14

Current Price

$13.46

$1.68 discount

UndervaluedFair: $15.14Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLPT2 strengths · Avg: 8.0/10
PEG RatioValuation
0.618/10

Growing faster than its price suggests

Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

CLPT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$418.52M3/10

Smaller company, higher risk/reward

Price/BookValuation
38.5x2/10

Trading at 38.5x book value

Return on EquityProfitability
-320.8%2/10

ROE of -320.8% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CLPT

The strongest argument for CLPT centers on PEG Ratio, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : CLPT

The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.93 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLPT profiles as a growth stock while MRK is a value play — different risk/reward profiles.

CLPT carries more volatility with a beta of 1.27 — expect wider price swings.

CLPT is growing revenue faster at 18.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clearpoint Neuro Inc

HEALTHCARE · MEDICAL DEVICES · USA

ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?